Trial reportEndocrinology, diabetes & metabolism2026
Metabolic and Antioxidant Status, Telomere Lengths of Individuals With Prediabetes in Context of 3 Months of Insoluble Dietary Fibre Intake During the SARS-CoV2 Pandemic.
Trial report in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04283201 (Development, Implementation and Evaluation of the Effectiveness of Recommendations for the Prevention of Type 2 Diabetes in Ukraine), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Development, Implementation and Evaluation of the Effectiveness of Recommendations for the Prevention of Type 2 Diabetes in Ukraine
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundInsoluble fibre (IF) may reduce the risk factors of type 2 diabetes development, but evidence on its short-term effects is limited. The influence of IF on oxidative stress markers, including reduced glutathione (GSH) and antioxidant enzymes, as well as on leukocyte telomere length (LTL), remains poorly studied. Coronavirus disease (COVID-19) occurring before or during IF interventions may influence study outcomes.
methodsThe study included 29 adults with impaired fasting glucose (IFG) who received 15 g/day of IF for 3 months. Seven participants had a recent history of COVID-19, defined as PCR-confirmed infection within 6 months before the intervention or COVID-19-like symptoms during the study. Fasting plasma glucose, 2-h plasma glucose (2hPG) during a WHO oral glucose tolerance test, glycated haemoglobin (HbA1c) and GSH were assessed at baseline and after 3 months. Fat mass (FM), blood pressure (BP), LTL, superoxide dismutase and catalase (CAT) were also measured.
resultsIn participants without COVID-19 (n = 22), IF intake was associated with reductions in 2hPG, HbA1c, FM and GSH, along with an increase in systolic BP. In the COVID-19 group (n = 7), HbA1c decreased, while both systolic and diastolic BP increased. No significant changes in LTL, superoxide dismutase or CAT levels were observed in either group.
conclusionShort-term IF supplementation in individuals with IFG improved selected glycaemic parameters but was accompanied by unexpected reductions in GSH and increases in blood pressure. These findings indicate complex physiological responses to IF that warrant further investigation.
trial registrationClinicalTrials.gov identifier: NCT04283201.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.